C
Charles Herbaux
Researcher at Harvard University
Publications - 126
Citations - 2870
Charles Herbaux is an academic researcher from Harvard University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 20, co-authored 94 publications receiving 2131 citations. Previous affiliations of Charles Herbaux include French Institute of Health and Medical Research & university of lille.
Papers
More filters
Journal ArticleDOI
The MLL recombinome of acute leukemias in 2013
Claus Meyer,Julia Hofmann,Thomas Burmeister,Daniela Gröger,T S Park,Mariana Emerenciano,M. Pombo De Oliveira,Aline Renneville,Patrick Villarese,Elizabeth Macintyre,Hélène Cavé,Emmanuelle Clappier,K. Mass-Malo,Jan Zuna,Jan Trka,E De Braekeleer,M. De Braekeleer,S H Oh,Grigory Tsaur,L Fechina,V H J van der Velden,J J M van Dongen,Eric Delabesse,Renata Binato,Mara Silva,AM Kustanovich,Olga V. Aleinikova,Marian H. Harris,T Lund-Aho,Vesa Juvonen,Olaf Heidenreich,Josef Vormoor,William W.L. Choi,Marie Jarošová,A. Kolenova,Clara Bueno,Pablo Menendez,S. Wehner,Cornelia Eckert,Pascaline Talmant,Sylvie Tondeur,Eric Lippert,E. Launay,Catherine Henry,Paola Ballerini,H. Lapillone,Mary Callanan,Jean Michel Cayuela,Charles Herbaux,Giovanni Cazzaniga,P. M. Kakadiya,Stefan K. Bohlander,Martina Ahlmann,Jong Rak Choi,Paula Gameiro,Dongsoon Lee,Juergen Krauter,Pascale Cornillet-Lefebvre,G te Kronnie,Beat W. Schäfer,S. Kubetzko,Cristina N. Alonso,U. Zur Stadt,Rosemary Sutton,N. C. Venn,Shai Izraeli,Luba Trakhtenbrot,H. O. Madsen,P. Archer,Jeremy Hancock,Nuno Cerveira,Manuel R. Teixeira,L Lo Nigro,Anja Möricke,Martin Stanulla,Martin Schrappe,Lukasz Sedek,Tomasz Szczepański,Christian M. Zwaan,Eva A. Coenen,M.M. van den Heuvel-Eibrink,Sabine Strehl,Michael Dworzak,Renate Panzer-Grümayer,Theodor Dingermann,Thomas Klingebiel,Rolf Marschalek +86 more
TL;DR: Long-distance inverse-polymerase chain reaction was used to characterize the chromosomal rearrangement of individual acute leukemia patients and revealed a total of 121 different MLL rearrangements, of which 79 TPGs are now characterized at the molecular level.
Journal ArticleDOI
Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström’s Macroglobulinemia
Meletios A. Dimopoulos,Alessandra Tedeschi,Judith Trotman,Ramón García-Sanz,David MacDonald,Véronique Leblond,Beatrice Mahe,Charles Herbaux,Constantine S. Tam,Lorella Orsucci,M. Lia Palomba,Jeffrey Matous,Chaim Shustik,Efstathios Kastritis,Steven P. Treon,Jianling Li,Zeena Salman,Thorsten Graef,Christian Buske +18 more
TL;DR: Among patients with Waldenström's macroglobulinemia, theUse of ibrutinib–rituximab resulted in significantly higher rates of progression‐free survival than the use of placebo–ritUXimab, both among those who had received no previous treatment and among those with disease recurrence.
Journal ArticleDOI
MYD88 L265P mutation in Waldenstrom macroglobulinemia
Stéphanie Poulain,Christophe Roumier,Audrey Decambron,Aline Renneville,Charles Herbaux,Charles Herbaux,Elisabeth Bertrand,Sabine Tricot,Agnès Daudignon,Sylvie Galiègue-Zouitina,Valérie Soenen,Olivier Theisen,Nathalie Grardel,Olivier Nibourel,Catherine Roche-Lestienne,Bruno Quesnel,Bruno Quesnel,Patrick Duthilleul,Claude Preudhomme,Xavier Leleu,Xavier Leleu +20 more
TL;DR: A whole exome-sequencing study of Waldenstrom macroglobulinemia confirmed a high frequency of MYD88 L265P mutation in WM, which may contribute to a better understanding of the physiopathogeny of WM.
Journal ArticleDOI
Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib
David Ghez,Anne Calleja,Caroline Protin,Marine Baron,Marie-Pierre Ledoux,Gandhi Damaj,Mathieu Dupont,Brigitte Dreyfus,Emmanuelle Ferrant,Charles Herbaux,Kamel Laribi,Ronan Le Calloch,Marion Malphettes,Franciane Paul,Laetitia Souchet,Malgorzata Truchan-Graczyk,Karen Delavigne,Caroline Dartigeas,Loic Ysebaert +18 more
TL;DR: It is indicated that ibrutinib may be associated with early-onset invasive fungal infections, in particular IA with frequent cerebral involvement, and that patients on ibrUTinib should be closely monitored in particular when other risk factors ofFungal infections are present.
Journal ArticleDOI
Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma.
Charles Herbaux,Jordan Gauthier,Pauline Brice,Elodie Drumez,Loic Ysebaert,Hélène Doyen,Luc-Matthieu Fornecker,Krimo Bouabdallah,Guillaume Manson,Hervé Ghesquières,Reza Tabrizi,Eric Hermet,Julien Lazarovici,Anne Thiebaut-Bertrand,Adrien Chauchet,Hélène Demarquette,Eileen M Boyle,Roch Houot,Ibrahim Yakoub-Agha,Franck Morschhauser +19 more
TL;DR: The results show that nivolumab is effective with an acceptable safety profile for patients with relapsed or refractory Hodgkin lymphoma and compared with standard options for this indication.